Reyon Pharmaceutical Co Ltd - Asset Resilience Ratio
Reyon Pharmaceutical Co Ltd (102460) has an Asset Resilience Ratio of 0.01% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 102460 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2024)
This chart shows how Reyon Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Reyon Pharmaceutical Co Ltd (102460) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Reyon Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Reyon Pharmaceutical Co Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩36.69 Million | 0.01% |
| Total Liquid Assets | ₩36.69 Million | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Reyon Pharmaceutical Co Ltd maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Reyon Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Reyon Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Reyon Pharmaceutical Co Ltd (2008–2024)
The table below shows the annual Asset Resilience Ratio data for Reyon Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | ₩6.04 Million ≈ $4.10K |
₩499.99 Billion ≈ $338.84 Million |
-0.03pp |
| 2023-12-31 | 0.03% | ₩134.02 Million ≈ $90.83K |
₩499.78 Billion ≈ $338.69 Million |
-4.10pp |
| 2022-12-31 | 4.13% | ₩20.02 Billion ≈ $13.57 Million |
₩484.69 Billion ≈ $328.47 Million |
-2.29pp |
| 2021-12-31 | 6.42% | ₩30.71 Billion ≈ $20.81 Million |
₩477.98 Billion ≈ $323.92 Million |
-4.05pp |
| 2020-12-31 | 10.48% | ₩33.27 Billion ≈ $22.55 Million |
₩317.61 Billion ≈ $215.24 Million |
-9.02pp |
| 2019-12-31 | 19.49% | ₩53.50 Billion ≈ $36.26 Million |
₩274.48 Billion ≈ $186.01 Million |
-27.48pp |
| 2018-12-31 | 46.97% | ₩142.40 Billion ≈ $96.50 Million |
₩303.17 Billion ≈ $205.45 Million |
+18.40pp |
| 2017-12-31 | 28.57% | ₩83.11 Billion ≈ $56.32 Million |
₩290.84 Billion ≈ $197.10 Million |
+11.74pp |
| 2016-12-31 | 16.83% | ₩35.27 Billion ≈ $23.91 Million |
₩209.54 Billion ≈ $142.00 Million |
+6.03pp |
| 2009-12-31 | 10.80% | ₩8.85 Billion ≈ $6.00 Million |
₩81.91 Billion ≈ $55.51 Million |
-2.11pp |
| 2008-12-31 | 12.91% | ₩8.43 Billion ≈ $5.71 Million |
₩65.27 Billion ≈ $44.23 Million |
-- |
About Reyon Pharmaceutical Co Ltd
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough … Read more